Tracks safety of Xeljanz in children with juvenile arthritis in Korea
Follows children aged 2 to 17 with juvenile idiopathic arthritis taking Xeljanz in routine care.
Plain-language title generated from the registry record
Registry title: Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
Source: NCT05754710, who can take part
Where in South Korea
- PfizerSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT05754710
- Record updated
- 3 August 2026
- Original description
This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study.Read full original descriptionShow less
KOREAN POST-MARKETING SURVEILLANCE FOR XELJANZ® 5 MG FILM-COATED TABLETS AND XELJANZ® 1 MG/ML ORAL SOLUTION IN PATIENTS WITH ACTIVE PJIA AND JPSA
This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study.
Xeljanz is a JAK inhibitor. It was first approved in 2014 for rheumatoid arthritis patients in Korea. The ministry of Food and Drug Safety in Korea mandates for a drug manufacturer to report the post-marketing surveillance after drug's approval or indication extension. This study is to see the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis patients in routine clinical practice in Korea.
This study is seeking patients who:
* Are 2 to less than 18 years of age; * Are given Xeljanz for the treatment of JIA.
The study sponsor will monitor patients' treatment experience for up to 44 weeks. This will help assess the safety and effects of this study medicine.
Inclusion: Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:; Pediatric subjects aged from 2 years to less than 18 years; Xeljanz administered according to efficacy/effectiveness on the approved labeling; Patients who will administer Xeljanz based on the medical judgement of the investigator; Evidence of a personally signed and dated informed consent document indicating that the subject (and a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion: Subjects meeting any of the following criteria will not be included in the study:; Subjects who are contraindicated from taking Xeljanz according to approved labeling*; *Refer to most recently approved label.